drugset

drugset / Trial / NCT01685996

Zonisamide Augmentation of Varenicline Treatment for Smoking Cessation

NCT01685996 ↗

Phase 1/2 Completed 74 enrolled Johns Hopkins University National Institute on Drug Abuse (NIDA) · collab

RandomizedParallel-groupTriple-blindTreatment

Summary

Randomized trial to evaluate whether zonisamide can enhance varenicline-induced smoking cessation.

Timeline

Start: 2012-09
Primary completion: 2014-05
Completion: 2014-05

Outcome

Missed primary endpoint

paper There were no differences between groups for biochemically-verified smoking PMID 26476459 ↗

Publications

Dunn KE, Marcus TF, Kim C, Schroeder JR, Vandrey R, Umbricht A. Zonisamide Reduces Withdrawal Symptoms But Does Not Enhance Varenicline-Induced Smoking Cessation. Nicotine Tob Res. 2016 May;18(5):1171-9. doi: 10.1093/ntr/ntv236. Epub 2015 Oct 17.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Zonisamide	Other / unclassified	300 mg	—

Indications